Core Viewpoint - Fuyuan Pharmaceutical, a well-known domestic pharmaceutical company, focuses on drug formulation and medical devices, showcasing strong R&D capabilities and a diverse product line [1] Group 1: Business Performance - In Q3 2025, Fuyuan Pharmaceutical reported revenue of 2.521 billion yuan, ranking 28th among 110 companies in the industry, with the industry leader, East China Pharmaceutical, generating 32.664 billion yuan [2] - The company's net profit for the same period was 378 million yuan, placing it 22nd in the industry, while the top performer, Hengrui Medicine, achieved a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Fuyuan Pharmaceutical's debt-to-asset ratio was 22.82%, lower than the industry average of 35.26% and down from 23.55% in the previous year [3] - The company's gross profit margin stood at 65.95%, slightly down from 67.09% year-on-year but still above the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman and general manager, Huang He, received a salary of 1.68 million yuan in 2024, an increase of 242,900 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.39% to 22,700, while the average number of circulating A-shares held per shareholder increased by 3.51% to 21,200 [5] Group 5: Research and Development - In the first half of 2025, Fuyuan Pharmaceutical's revenue was 1.634 billion yuan, a year-on-year decline of 1.3%, with a net profit of 268 million yuan, down 7.83% [6][7] - The company has a rich pipeline of generic drugs, with 11 applications submitted for approval in the first half of the year, and is advancing research on small nucleic acid drugs [6][7]

Group 1 - The core point of the article highlights the recent performance of Fuyuan Pharmaceutical, which saw a 5.36% increase in stock price, reaching 22.98 yuan per share, with a trading volume of 100 million yuan and a turnover rate of 0.93%, resulting in a total market capitalization of 11.03 billion yuan [1] - Fuyuan Pharmaceutical, established on February 3, 1999, and listed on June 30, 2022, is primarily engaged in the research, production, and sales of pharmaceutical preparations and medical devices, with 94.09% of its revenue coming from pharmaceutical preparations and 6.00% from medical devices [1] Group 2 - Among the top ten circulating shareholders of Fuyuan Pharmaceutical, E Fund's healthcare mixed fund A (110023) entered the list in the third quarter, holding 2.5638 million shares, which accounts for 0.53% of the circulating shares, with an estimated floating profit of approximately 2.9996 million yuan [2] - E Fund's healthcare mixed fund A (110023), established on January 28, 2011, has a latest scale of 3.802 billion yuan, with a year-to-date return of 31.25%, ranking 3013 out of 8154 in its category, and a one-year return of 22.68%, ranking 3972 out of 8046 [2] - The fund manager, Yang Zhenshao, has been in the position for 9 years and 75 days, managing a total fund asset size of 9.816 billion yuan, with the best fund return during his tenure being 209.89% and the worst being -14.74% [2]

Core Viewpoint - Fuyuan Pharmaceutical (601089) reported that its current business operations are normal and all business segments are progressing steadily [1] Company Summary - The company is actively engaging with investors and providing updates on its operational status [1] - Fuyuan Pharmaceutical emphasizes stability in its business activities, indicating a positive outlook for ongoing operations [1]

北京福元医药股份有限公司 关于取消监事会、增加董事会席位、修订《公司章程》 及修订、制定部分治理制度的公告 证券代码：601089 证券简称：福元医药 公告编号：临2025-071 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京福元医药股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开了 第三届董事会第三次会议和第三届监事会第三次会议，分别审议通过了《关于取消 监事会、增加董事会席位、修订<公司章程>并办理工商变更登记的议案》。现将有 关情况公告如下： 一、取消监事会 公司拟不再设置监事会，同时免去监事职务，监事会的职权由董事会审计委员会 行使。同时，公司《监事会议事规则》相应废止。 二、增加董事会席位 公司为进一步提高董事会决策的科学性和有效性，拟新增 1 名职工代表董事， 将董事会席位由 8 名增加至 9 名，独立董事 3 名保持不变，非独立董事由 5 名增加 至 6 名。 三、修订《公司章程》 根据《中华人民共和国公司法》《上市公司章程指引》等相关法律法规和规范 性文件的规定，结合公司实际情况 ...

Group 1 - The core point of the article is that Fuyuan Pharmaceutical (601089.SH) reported its Q3 2025 results, highlighting significant institutional ownership and changes in fund holdings [1] - As of October 29, 2025, a total of 8 institutional investors hold shares in Fuyuan Pharmaceutical, with a combined holding of 361 million shares, representing 75.30% of the total share capital [1] - The institutional ownership decreased by 0.16 percentage points compared to the previous quarter [1] Group 2 - In terms of public funds, 2 new public funds were disclosed this quarter, including E Fund Healthcare Industry Mixed A and Ping An New Xin Pioneer Mixed A [1] - A total of 72 public funds were not disclosed this quarter compared to the previous quarter, including several ETFs and mixed funds [1] - Regarding foreign investment, one foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.26% this quarter [2]

Core Points - The company has announced its third quarter report for 2025, ensuring the accuracy and completeness of the financial information presented [1][6][22] - The board of directors and the supervisory board have approved several key resolutions, including the completion of a high-tech pharmaceutical project and the adjustment of fundraising projects [8][9][27] - The company plans to permanently supplement its working capital with surplus funds from completed projects, amounting to approximately 171.36 million yuan [35][36] Financial Data - The company reported that as of September 30, 2025, it had a total of 12 million shares in its repurchase account, representing 2.50% of the total share capital [3] - The company has not conducted an audit for the third quarter financial statements [1][4] - The financial report includes details on non-recurring gains and losses, which are applicable [1][2] Shareholder Information - The total number of ordinary shareholders and the status of preferred shareholders with restored voting rights were not applicable [2] - The company has outlined the shareholding situation of its top ten shareholders [2] Board Meeting Resolutions - The board meeting held on October 28, 2025, approved the third quarter report and several other significant resolutions [8][9][10] - The board has proposed to cancel the supervisory board and increase the number of board seats, which will require shareholder approval [15][30] Project Adjustments - The company has completed the high-tech pharmaceutical project and plans to use the remaining funds for daily operations [35][36] - Adjustments to the innovative drug and generic drug research projects have been made, with some projects being postponed until December 2026 [40][43] Upcoming Shareholder Meeting - The second extraordinary general meeting of shareholders is scheduled for November 14, 2025, with both onsite and online voting options available [58][59]

Group 1 - The company, Fuyuan Pharmaceutical, announced the convening of its third board meeting on October 28, 2025, to discuss the senior management compensation plan [1] - For the fiscal year 2024, the revenue composition of Fuyuan Pharmaceutical is as follows: 93.12% from pharmaceutical preparations, 6.46% from medical devices, 0.36% from other businesses, and 0.06% from other sources [1] - As of the report date, Fuyuan Pharmaceutical has a market capitalization of 10.6 billion yuan [1]

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The total operating revenue for the first three quarters reached 2.521 billion yuan, representing a year-on-year decrease of 1.04% [1] - The net profit attributable to shareholders of the parent company was 375 million yuan, down 6.39% year-on-year [1] - The basic earnings per share stood at 0.78 yuan [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-075 北京福元医药股份有限公司 关于公司参与第十一批全国药品集中采购 拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 10 月 27 日至 10 月 28 日，北京福元医药股份有限公司（以下简称"公 司"）参加了国家组织药品联合采购办公室（以下简称"联采办"）组织的第十一 批全国药品集中采购的投标工作。经联采办开标、评标后，公司 6 个产品拟中标本 次集中采购，现将相关情况公告如下： | 序号 | 品种名称 | 药品适应症 | 规格包装 | 拟中选价格 | 用于成年人和青少 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 富 | 马 | 酸 | 卢 | 帕 | 他 | 年（12 | 岁以上）过 | 1 | 10mg*30 | 片 | 32.59 | 元 ...

中信建投证券股份有限公司关于北京福元医药股份有限公司 部分募投项目结项并将节余募集资金永久补充流动资金及调整募投 项目部分实施内容并延期的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为北京福元医药股份有限公司（以下简称"福元医药"、"公司"）首次公开 发行股票并上市项目的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》等相关规定履行持续 督导职责，对福元医药部分募投项目结项并将节余募集资金永久补充流动资金及 调整募投项目部分实施内容并延期的情况进行了审慎核查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准北京福元医药股份有限公司首次公 开发行股票的批复》（证监许可[2022]974号）核准，公司首次公开发行人民币 普通股（A股）股票12,000万股，发行价格为人民币14.62元/股，募集资金总额 为人民币1,754,400,000.00元，扣除不含增值税发行费用人民币118,480,188.68元 后，募集资金净额为人民币1,635,919,811.32元。 首次公开发行股票的募集资金于2 ...